PH12019501186A1 - Tyrosine derivatives and composition comprising them - Google Patents

Tyrosine derivatives and composition comprising them

Info

Publication number
PH12019501186A1
PH12019501186A1 PH12019501186A PH12019501186A PH12019501186A1 PH 12019501186 A1 PH12019501186 A1 PH 12019501186A1 PH 12019501186 A PH12019501186 A PH 12019501186A PH 12019501186 A PH12019501186 A PH 12019501186A PH 12019501186 A1 PH12019501186 A1 PH 12019501186A1
Authority
PH
Philippines
Prior art keywords
composition
tyrosine hydroxylase
hydroxylase inhibitor
tyrosine derivatives
subject
Prior art date
Application number
PH12019501186A
Inventor
Steven Hoffman
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of PH12019501186A1 publication Critical patent/PH12019501186A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and kits comprising a tyrosine hydroxylase inhibitor and an anticancer agent that is chemically bonded to, or physically associated with, the tyrosine hydroxylase inhibitor are provided. Also provided are methods for reducing cell proliferation in a subject comprising administering to a subject in need thereof a composition comprising a tyrosine hydroxylase inhibitor and an anticancer agent that is chemically bonded to, or physically associated with, the tyrosine hydroxylase inhibitor.
PH12019501186A 2016-11-30 2019-05-29 Tyrosine derivatives and composition comprising them PH12019501186A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
PH12019501186A1 true PH12019501186A1 (en) 2020-02-10

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019501186A PH12019501186A1 (en) 2016-11-30 2019-05-29 Tyrosine derivatives and composition comprising them

Country Status (12)

Country Link
EP (1) EP3548086A1 (en)
JP (2) JP2019536783A (en)
KR (1) KR20190089191A (en)
CN (1) CN110062633A (en)
AU (1) AU2017368135A1 (en)
BR (1) BR112019011033A2 (en)
CA (1) CA3045110A1 (en)
EA (1) EA201991305A1 (en)
IL (1) IL266840A (en)
MX (1) MX2019006326A (en)
PH (1) PH12019501186A1 (en)
WO (1) WO2018102506A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (en) * 2019-03-26 2020-10-09 深圳先进技术研究院 Use of alpha-methyl tyrosine or its derivative
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
US20210220312A1 (en) * 2020-01-17 2021-07-22 Tyme, Inc. Compositions And Methods For Modulating Cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP3075247B1 (en) * 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
AU2006342202C1 (en) * 2006-04-19 2013-09-26 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP3488848A1 (en) * 2012-01-17 2019-05-29 Tyme, Inc. Tyrosine hydroxylase inhibitors for use in treating cancer
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
EA201991305A1 (en) 2019-10-31
WO2018102506A1 (en) 2018-06-07
CA3045110A1 (en) 2018-06-07
JP2019536783A (en) 2019-12-19
BR112019011033A2 (en) 2019-10-15
AU2017368135A1 (en) 2019-06-13
CN110062633A (en) 2019-07-26
MX2019006326A (en) 2019-07-12
JP2022153587A (en) 2022-10-12
EP3548086A1 (en) 2019-10-09
KR20190089191A (en) 2019-07-30
IL266840A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
CR20190478A (en) Pd-1/pd-l1 inhibitors
PH12019501186A1 (en) Tyrosine derivatives and composition comprising them
CR20210013A (en) Pd-1/pd-l1 inhibitors
MY195110A (en) Antibodies to PD-1 and uses Thereof
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
MX2017013613A (en) Cancer neoepitopes.
MY199019A (en) Pd-1 antibodies
CL2016001231A1 (en) Autotaxin Inhibitor Compounds
MX2019007276A (en) Compositions and methods of enhancing or augmenting type i ifn production.
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
TWD173671S (en) Communications headset
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
CR20110553A (en) COMPLEMENTARY THERAPY AGAINST CANCER
WO2019006005A3 (en) Methods and compositions for treating melanoma
MX2015013177A (en) Combination cancer treatments utilizing micrornas and egfr-tki inhibitors.
MX2017008414A (en) Nitrification inhibitor compositions and methods for preparing the same.
MX2017011521A (en) Topical compositions comprising a corticosteroid.
WO2017132746A8 (en) Ubiquitin variants and uses thereof as 53bp1 inhibitors
MX2015009818A (en) Pparî³ agonists for treatment of multiple sclerosis.
MX2021008839A (en) Binder compositions and methods for making and using same.
WO2018009507A8 (en) Combination oftim-4 antagonist and pd-1 antagonist and methods of use
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
EA202191631A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS